A new bufadienolide named dyscinobufotalin (1), along with twenty known bufadienolides (2–21) were isolated from the venom of Bufo bufo gargarizans. Their structures were elucidated by spectroscopic analysis. The absolute configuration of the new natural product 2 was determined by X-ray single crystal diffraction and the complete NMR data for 3 was delivered for the first time. Both compounds 4 and 8 showed comparable α-glucosidase inhibitory activity (IC50 values of 0.25 and 0.26 μM, respectively) to the positive control acarbose (IC50 value of 0.42 μM), and 5 displayed potent inhibitory activity on acetylcholinesterase with an IC50 value of 0.12 μM. Moreover, 5, 8 and 13 presented moderate toxicity against brine shrimp.
DaiL.P., GaoH.M., WangZ.M., WangW.H. (2007) Isolation and structure identification of chemical constituents from the skin of Bufo bufo gargarizans.Acta Pharmaceutica Sinica, 42, 858–861.
2.
McGlackenM.P., FairlambI.J.S. (2005) 2-Pyrone natural products and mimetics: isolation, characterisation and biological activity. Natural Product Reports, 22, 369–385.
3.
SteynP.S., Van HeerdeenF.R. (1998) Bufadienolides of plant and animal origin. Natural Product Reports, 15, 397–413.
4.
MorenoY., BanulsL., UrbanE., GelbckeM., DufrasneF., KoppB., KissR., ZehlM. (2013) Structure-activity relationship analysis of bufadienolide-Induced in vitro growth inhibitory effects on mouse and human cancer cells. Journal of Natural Products, 76, 1078–1084.
5.
YeM., QuG.Q., GuoH.Z., GuoD.A. (2004) Novel cytotoxic bufadienolides derived from bufalin by microbial hydroxylation and their structure-activity relationships. Journal of Steroid Biochemistry & Molecular Biology, 91, 87–98.
6.
TianH.Y., ZhangP.W., LiuJ.S., ZhangD.M., ZhangX.Q., JiangR.W., YeW.C. (2014) New cytotoxic C-3 dehydrated bufadienolides from the venom of Bufo bufo gargarizans.Chinese Chemical Letters, 25, 1104–1106.
7.
KamanoY., YamashitaA., NogawaT., MoritaH., TakeyaK., ItokawaH. (2002) QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5. Journal of Medicinal Chemistry, 45, 5440–5447.
8.
LuoS.L., TianH.Y., LiuJ.S., WangY., YeW.C. (2015) A new C23 steroid from the venom of Bufo bufo gargarizans.Natural Product Communications, 10, 1353–1354.
9.
BickR.J., PoindexterB.J., SweneyR.R., DasguptaA. (2002) Effects of Chan Su, a traditional Chinese medicine, on the calcium transients of isolated cardiomyocytes: cardiotoxicity due to more than Na, K-ATPase blocking. Life Sciences, 72, 699–709.
10.
MaH.Y., KouJ.P., ZhuD., YanY.Q., YuB.Y. (2006) Liu-Shen-Wan. a traditional Chinese medicine, improves survival in sepsis induced by cecal ligation and puncture via reducing TNF-alpha levels, MDA content and enhancing macrophage phagocytosis. International Immunopharmacology, 6, 1355–1362.
11.
KamanoY., HatayamaK., ShinoharaM., KomatsuM. (1971) Bufadienolides. IX. Isolation and structure of resibufagin. Chemical and Pharmaceutical Bulletin, 19, 2478–2484.
12.
ReynoldsW.F., MaxwellA., TelangB., BedaisietK., RamcharanG. (1995) Total assignment of the 1H and 13C NMR chemical shifts of four bufadienolides by 2D NMR spectroscopy. Magnetic Resonance in Chemistry, 33, 412–414.
13.
Cunha-FilhoG.A., ResckI.S., CavalcantiB.C., PessoaCÓ, MoraesM.O., FerreiraJ.R., dos SantosM.L. (2010) Cytotoxic profile of natural and some modified bufadienolides from toad Rhinella schneideri parotoid gland secretion. Toxicon, 56, 339–348.
14.
YeM., NingL.L., ZhanJ.X., GuoH.Z., GuoD.A. (2003) Biotransformation of cinobufagin by cell suspension cultures of Catharanthus roseus and Platycodon grandiflorum.Journal of Molecular Catalysis B: Enzymatic, 22, 89–95.
15.
YeM., GuoH., GuoH.Z., HanJ., GuoD.A. (2006) Simultaneous determination of cytotoxic bufadienolides in the Chinese medicine ChanSu by high-performance liquid chromatography coupled with photodiode array and mass spectrometry detections. Journal of Chromatography B, 838, 86–95.
16.
ZhangX., YeM., DongY.H., HuH.B., TaoS.J., YinJ., GuoD.A. (2011) Biotransformation of bufadienolides by cell suspension cultures of Saussurea involucrata.Phytochemistry, 72, 1779–1785.
17.
LiX.L., GuoZ.M., WangC.R., ShenA.J., LiuY.F., ZhangX.L., ZhaoW.J., LiangX.M. (2014) Purification of bufadienolides from the skin of Bufo bufo gargarizans Cantor with positively charged C18 column. Journal of Pharmaceutical and Biomedical Analysis, 92, 105–113.
18.
ZhangP.W., JiangR.W., YeW.C., TianH.Y. (2014) Bufadienolides from venom of Bufo bufo gargarizans.China Journal of Chinese Materia Medica, 39, 841–845.
19.
VerpoorteR., SvendsenA.B. (1980) Chemical constituent of Vietnamese toad venom, collected from Bufo melanostictus Schneider. Part II: The bufodienolides. Journal of Natural Products, 43, 347–352.
20.
NogawaT., KamanoY., YamashitaA., PettitG.R. (2001) Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. Journal of Natural Products, 64, 1148–1152.
21.
YoshiakiK., HiroshiY., KatsuoH., YoshihiroT., MichikoS., MankiK. (1968) The isolation and structure of new bufadienolide, resibufagin and the isolation of marinobufagin. Tetrahedron Letters, 9, 5669–5672.
22.
FanP.H., TerrierL., HayA.E., MarstonA., HostettmannK. (2010) Antioxidant and enzyme inhibition activities and chemical profiles of Polygonum sachalinensis F. Schmidt ex Maxim (Polygonaceae). Fitoterapia, 81, 124–131.
23.
LiT., ZhangX.D., SongY.W., LiuJ.W. (2005) A microplate-based screening method for alpha-glucosidase inhibitors. Chinese Journal of Clinical Pharmacology and Therapeutics, 10, 1128–1134.
24.
EllmanG.L., CourtneyK.D., AndresV., FeatherstoneR.M. (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology, 7, 88–95.
25.
LiX.J., TangH.Y., DuanJ.L., GaoJ.M., XueQ.H. (2013) Bioactive alkaloids produced by Pseudomonas brassicacearum subsp. neoaurantiaca, an endophytic bacterium from Salvia miltiorrhiza. Natural Product Research, 27, 496–499.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
